Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) began trading on the New York Stock Exchange yesterday after transferring from Nasdaq. The pharmaceuticals giant will remain dual listed on the Tel Aviv Stock Exchange (TASE).
Teva chairman Dr. Phillip Frost and president and CEO Dr. Jeremy Levin along with a group of employees representing Teva’s businesses around the world, rang the Opening Bell at the NYSE yesterday to celebrate the move. The company's shares continue to trade under its ticker symbol “TEVA.”
Frost said, “We are pleased to partner with the NYSE and begin using their state of the art trading platform and market research. We are joining a network of true innovators and leaders listed on the NYSE.”
Teva had been the second largest company trading on Nasdaq and is the seventh company this year to transfer from Nasdaq to the NYSE.
NYSE Euronext head of international listings Diederik Zandstra said, “We are proud that Teva has chosen to transfer to the NYSE and recognizes the value of our global community, market structure and technology. We look forward to our partnership with Teva and its shareholders."
Published by Globes [online], Israel business news - www.globes-online.com - on May 31, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012